Jiangsu Kanion Pharmaceutical Co.,Ltd. — Investor Relations & Filings
About Jiangsu Kanion Pharmaceutical Co.,Ltd.
Jiangsu Kanion Pharmaceutical Co.,Ltd. focuses on the research, development, and manufacturing of modern Traditional Chinese Medicine (TCM). The company specializes in therapeutic categories including anti-viral, cardiovascular, gynecological, and pediatric treatments. Key products include Re-Du-Ning Injection and Guizhi Fuling Capsules. Kanion is distinguished by its integration of advanced pharmaceutical technology with traditional herbal medicine, employing intelligent manufacturing systems and standardized extraction processes. Its R&D efforts prioritize the clinical validation and modernization of TCM formulations to address complex health conditions. The company serves a broad market by providing evidence-based botanical therapies developed through rigorous scientific methodology and high-tech production standards.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 江苏康缘药业股份有限公司关于收到青参通络颗粒临床试验批准通知书的公告 | 2026-04-19 | Chinese | |
| 江苏康缘药业股份有限公司关于聘任副总经理的公告 | 2026-03-30 | Chinese | |
| 江苏康缘药业股份有限公司关于收到黑黄赤珠颗粒临床试验批准通知书的公告 | 2026-02-25 | Chinese | |
| 江苏康缘药业股份有限公司关于聘任副总经理的公告 | 2026-02-24 | Chinese | |
| 江苏康缘药业股份有限公司关于收到运脾化痰通窍颗粒临床试验批准通知书的公告 | 2026-01-26 | Chinese | |
| 江苏康缘药业股份有限公司关于收到车前子片临床试验批准通知书的公告 | 2026-01-20 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
6 filings
| |||||
| 41124557 | 江苏康缘药业股份有限公司关于收到青参通络颗粒临床试验批准通知书的公告 | 2026-04-19 | Chinese | ||
| 41124554 | 江苏康缘药业股份有限公司关于聘任副总经理的公告 | 2026-03-30 | Chinese | ||
| 41124549 | 江苏康缘药业股份有限公司关于收到黑黄赤珠颗粒临床试验批准通知书的公告 | 2026-02-25 | Chinese | ||
| 41124541 | 江苏康缘药业股份有限公司关于聘任副总经理的公告 | 2026-02-24 | Chinese | ||
| 41124536 | 江苏康缘药业股份有限公司关于收到运脾化痰通窍颗粒临床试验批准通知书的公告 | 2026-01-26 | Chinese | ||
| 41124528 | 江苏康缘药业股份有限公司关于收到车前子片临床试验批准通知书的公告 | 2026-01-20 | Chinese | ||
|
2025
9 filings
| |||||
| 41124517 | 江苏康缘药业股份有限公司关联交易决策制度（2025年12月修订） | 2025-12-29 | Chinese | ||
| 41124507 | 江苏世纪同仁律师事务所关于江苏康缘药业股份有限公司2025年第一次临时股东会的法律意见书 | 2025-12-29 | Chinese | ||
| 41124496 | 江苏康缘药业股份有限公司关于选举第八届董事会职工代表董事的公告 | 2025-12-29 | Chinese | ||
| 41124487 | 江苏康缘药业股份有限公司公司章程（2025年12月修订） | 2025-12-29 | Chinese | ||
| 41124475 | 江苏康缘药业股份有限公司股东会议事规则（2025年12月修订） | 2025-12-29 | Chinese | ||
| 41124467 | 江苏康缘药业股份有限公司董事会议事规则（2025年12月修订） | 2025-12-29 | Chinese | ||
| 41124456 | 江苏康缘药业股份有限公司独立董事工作制度（2025年12月修订） | 2025-12-29 | Chinese | ||
| 41124450 | 江苏康缘药业股份有限公司募集资金管理办法（2025年12月修订） | 2025-12-29 | Chinese | ||
| 41124443 | 江苏康缘药业股份有限公司2025年第一次临时股东会决议公告 | 2025-12-29 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Jiangsu Kanion Pharmaceutical Co.,Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56814/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56814 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56814 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56814 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56814}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Jiangsu Kanion Pharmaceutical Co.,Ltd. (id: 56814)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.